Frankfurt
18.07.25 | 08:24
0,819 Euro
+0,74 % +0,006
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.06. | DIAMYD MEDICAL AB: Quarterly Report 3 24/25 | 2 | Cision News | ||
| 25.06. | Diamyd Medical AB (publ): Quarterly Report 3 24/25 | 82 | GlobeNewswire (Europe) | Precision Medicine for Autoimmune Diabetes
Aiming for Accelerated Market Approval
Autoimmune or Type-1 Diabetes (T1D) is a progressive disease, diagnosed as at least two antibodies to the insulin producing... ► Artikel lesen | |
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 16.06. | DIAMYD MEDICAL AB: Diamyd Medical to participate in two key US diabetes events | 11 | Cision News | ||
| 19.05. | Diamyd Medical AB (publ): Diamyd Medical appoints Niklas Axelsson as CFO | 129 | GlobeNewswire (Europe) | Niklas Axelsson has been appointed CFO of Diamyd Medical. He will assume his position in August and will also join the management team. Niklas Axelsson brings more than 25 years of experience across... ► Artikel lesen | |
| 15.05. | DIAMYD MEDICAL AB: Adjustment of the number of shares and share capital in Diamyd Medical, receives SEK 1.6 million more than previously communicated | 4 | Cision News | ||
| 05.05. | DIAMYD MEDICAL AB: Diamyd Medical has expanded the recently completed rights issue with a directed new issue of SEK 41.6 million | 8 | Cision News | ||
| 30.04. | DIAMYD MEDICAL AB: Diamyd Medical announces final outcome in oversubscribed rights issue: SEK 224 million | 3 | Cision News | ||
| 30.04. | DIAMYD MEDICAL AB: Diamyd Medical updates the preliminary outcome and will exercise the additional unit issue following the oversubscribed rights issue, raising approximately SEK 224 million | 2 | Cision News | ||
| 29.04. | DIAMYD MEDICAL AB: Diamyd Medical's rights issue has been preliminarily subscribed to 95 percent, thereby raising approximately SEK 198 million | 1 | Cision News | ||
| 28.04. | DIAMYD MEDICAL AB: Last day of the subscription period in Diamyd Medicals rights issue | 1 | Cision News | ||
| 28.04. | DIAMYD MEDICAL AB: Europe to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes | 1 | Cision News | ||
| 25.04. | Diamyd Medical AB (publ): Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears second-to-last safety review ahead of early readout in March 2026 | 135 | GlobeNewswire (Europe) | The independent Data Safety Monitoring Board (DSMB) has completed its fifth scheduled safety review of Diamyd Medical's registrational Phase 3 trial, DIAGNODE-3, evaluating the precision medicine immunotherapy... ► Artikel lesen | |
| 22.04. | DIAMYD MEDICAL AB: Shareholders in Diamyd Medical, including the Chairman of the Board, have provided additional subscription commitments in the ongoing rights issue | 2 | Cision News | ||
| 21.04. | Diamyd Medical AB: Diamyd Medical highlights opportunity in Type 1 Diabetes prevention, adult-onset market, and upcoming Phase 3 readout | 313 | PR Newswire | STOCKHOLM, April 21, 2025 /PRNewswire/ -- In a recent investor interview, Diamyd Medical Board Member Professor Mark Atkinson and CEO Ulf Hannelius shared key insights into the Company's... ► Artikel lesen | |
| 17.04. | DIAMYD MEDICAL AB: The prevention trial DiaPrecise with Diamyd® clears first safety milestone | 1 | Cision News | ||
| 15.04. | Diamyd Medical AB (publ): Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment | 153 | GlobeNewswire (Europe) | The Australian Patent Office has granted a patent protecting a novel immunotherapeutic composition developed by Diamyd Medical for use in the treatment and prevention of autoimmune diabetes. The patent... ► Artikel lesen | |
| 14.04. | DIAMYD MEDICAL AB: Diamyd Medical publishes prospectus with regards to the rights issue | 1 | Cision News | ||
| 09.04. | Diamyd Medical AB (publ): Quarterly Report 2 24/25 | 141 | GlobeNewswire (Europe) | Diamyd Medical today announces in its second quarterly report for fiscal year 2024/2025 continued progress toward a transformative regulatory milestone, with early Phase 3 results from the DIAGNODE-3... ► Artikel lesen | |
| 09.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.04.2025 | 155 | Xetra Newsboard | Das Instrument N7S CA87043J2039 SWEET POISON SPIRITS INC. EQUITY wird cum Kapitalmassnahme gehandelt am 09.04.2025 und ex Kapitalmassnahme am 10.04.2025 The instrument N7S CA87043J2039 SWEET POISON... ► Artikel lesen | |
| 21.03. | DIAMYD MEDICAL AB: Diamyd Medical announces additional subscription commitments for upcoming rights issue | 1 | Cision News |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 162,40 | -0,37 % | Dividendenbekanntmachungen (15.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,59 USD 0,5058 EUR ABBVIE INC US00287Y1091 1,64 USD 1,4059 EUR ARCOSA INC US0396531008 0,05... ► Artikel lesen | |
| INNOCAN PHARMA | 0,133 | +1,92 % | Neue Studie: Gamechanger für Innocan Pharma?! | ||
| ABBOTT LABORATORIES | 106,66 | +0,23 % | FreeStyle Libre Messsystem für Menschen mit Diabetes Typ 2 / Abbott gibt Kooperation mit vier privaten Krankenversicherungen bekannt | Wiesbaden (ots) - Für Menschen mit Typ-1-Diabetes ist die Verschreibung und Erstattung von Systemen zur kontinuierlichen Glukosemessung (CGM) längst Standard, aber ab sofort können auch mehr Menschen... ► Artikel lesen | |
| ARZNEIWERK AG VIDA | 0,300 | -36,97 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 30.06.2025 | The following instruments on XETRA do have their last trading day on 30.06.2025Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 30.06.2025ISIN NameDE000A3EX3G0 GORE German Office... ► Artikel lesen | |
| ZOETIS | 127,86 | +0,03 % | Dividendenbekanntmachungen (18.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A-MARK PRECIOUS METALS INC US00181T1079 0,2 USD 0,1724 EUR ACUITY INC US00508Y1029 0,17 USD 0,1465 EUR BHARTI AIRTEL LTD INE397D01024 16... ► Artikel lesen | |
| CRESCO LABS | 0,461 | -2,62 % | Cresco Labs Inc: Cresco Labs to release Q2 results Aug. 7 | ||
| CSPC PHARMA | 1,011 | +1,13 % | AstraZeneca Signs Nearly $5.3 Bln AI-enabled Research Deal With China's CSPC Pharma | LONDON (dpa-AFX) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Friday that it has entered into a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 39,800 | -1,49 % | Pre-market Movers: Creative Global Technology, Liminatus Pharma, CureVac, Jupiter Neurosciences, Tonix Pharmaceuticals | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.05 A.M. ET).In the Green Creative Global Technology Holdings Limited (CGTL)... ► Artikel lesen | |
| AMARIN | 14,000 | +2,19 % | Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus | ||
| NEKTAR THERAPEUTICS | 21,200 | -1,17 % | Nektar Therapeutics Prices $100 Mln Public Offering Of Common Stock At $23.50 Per Share | WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR), a clinical-stage biotech firm specializing in immunotherapy, has priced its underwritten public offering of approximately $100 million in common... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 95,90 | -0,21 % | Mizuho bestätigt Outperform-Rating für Axsome Therapeutics vor F&E-Tag | ||
| WUXI BIOLOGICS | 3,007 | -2,07 % | Aktienmarkt: Kurs der WuXi Biologics-Aktie im Plus (2,9005 €) | Im Plus liegt derzeit die WuXi Biologics-Aktie . Der jüngste Kurs betrug 2,90 Euro. Freuen können sich gegenwärtig die Aktionäre von WuXi Biologics: Das Wertpapier weist gegenwärtig ein Kursplus von... ► Artikel lesen | |
| JAGUAR HEALTH | 2,320 | 0,00 % | Jaguar Health, Inc.: Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs | Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally approved for CID, to regulatory approval and commercialization... ► Artikel lesen | |
| DAIICHI SANKYO | 20,890 | +0,72 % | Daiichi Sankyo and AstraZeneca's Enhertu gains breakthrough therapy status | ||
| ACADIA PHARMACEUTICALS | 19,415 | -0,05 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study... ► Artikel lesen |
Das Unternehmen DIAMYD MEDICAL AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,819 Euro und damit +0,74 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.